NCT06720922Recruiting
MRgLITT for mTLE: A PROBE Trial
Magnetic Resonance-guided Laser Interstitial Thermal Therapy for Mesial Temporal Lobe Epilepsy: A Prospective, Randomized, Open Blinded, End-point Trial
Source: ClinicalTrials.gov · Last updated 21 Jan 2026
Brief summary (registry, in English)
How does magnetic resonance-guided laser interstitial thermal therapy (MRgLITT) impact clinical prognosis in mesial temporal lobe epilepsy (mTLE)?
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 3 Dec 2024
- Start date
- 21 Jul 2025
- Primary completion date
- 1 Jan 2027
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Epilepsy
- NCT number
- NCT06720922
What you commit to
- Study type: Interventional
- Planned participants: 120
- From 21 Jul 2025 to the primary completion date, 1 Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of brain surgery.
- Individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections.
Other
- Intracranial space occupying lesions.
Who the study is looking for
- 18-65 years.
- Drug-resistant mesial temporal lobe epilepsy.
- Seizure frequency ≥ 1 time /month.
- Participants approved.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.